Published in Adv Cancer Res on February 07, 2015
Two-Dimensional N-Glycan Distribution Mapping of Hepatocellular Carcinoma Tissues by MALDI-Imaging Mass Spectrometry. Biomolecules (2015) 0.80
Comprehensive N-glycan profiles of hepatocellular carcinoma reveal association of fucosylation with tumor progression and regulation of FUT8 by microRNAs. Oncotarget (2016) 0.79
Hijacking the Hexosamine Biosynthetic Pathway to Promote EMT-Mediated Neoplastic Phenotypes. Front Oncol (2016) 0.76
Therapeutic Targeting of Epithelial Plasticity Programs: Focus on the Epithelial-Mesenchymal Transition. Cells Tissues Organs (2017) 0.75
Profiling of core fucosylated N-glycans using a novel bacterial lectin that specifically recognizes α1,6 fucosylated chitobiose. Sci Rep (2016) 0.75
Intrinsic hepatocyte dedifferentiation is accompanied by upregulation of mesenchymal markers, protein sialylation and core alpha 1,6 linked fucosylation. Sci Rep (2016) 0.75
FUT8 promotes breast cancer cell invasiveness by remodeling TGF-β receptor core fucosylation. Breast Cancer Res (2017) 0.75
Marsdeniae tenacissima extract-induced growth inhibition and apoptosis in hepatoma carcinoma cells is mediated through the p53/nuclear factor-κB signaling pathway. Exp Ther Med (2017) 0.75
A pilot study of salivary N-glycome in HBV-induced chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Glycoconj J (2017) 0.75
Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med (1999) 17.03
Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer (1999) 8.61
Intracellular functions of N-linked glycans. Science (2001) 8.39
Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer (1988) 7.05
Increase in primary liver cancer in the UK, 1979-94. Lancet (1997) 6.15
Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med (2003) 5.45
Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation. Cell (2007) 4.85
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
Epidemiology of primary liver cancer. Semin Liver Dis (1999) 4.48
Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. Hepatology (2009) 4.03
The treatment of chronic viral hepatitis. N Engl J Med (1997) 3.97
Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell (2008) 3.95
Molecular viral oncology of hepatocellular carcinoma. Oncogene (2003) 3.58
Integrated pipeline for mass spectrometry-based discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancer. J Proteome Res (2007) 3.48
Glycoprotein glycosylation and cancer progression. Biochim Biophys Acta (1999) 3.17
P-selectin deficiency attenuates tumor growth and metastasis. Proc Natl Acad Sci U S A (1998) 3.02
Beta 1-6 branching of Asn-linked oligosaccharides is directly associated with metastasis. Science (1987) 2.86
Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proc Natl Acad Sci U S A (2005) 2.70
GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol (2005) 2.70
N-glycans as apical sorting signals in epithelial cells. Nature (1995) 2.68
A decade's studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol (2003) 2.50
Osteopontin-c is a selective marker of breast cancer. Int J Cancer (2008) 2.20
Identification and development of fucosylated glycoproteins as biomarkers of primary hepatocellular carcinoma. J Proteome Res (2009) 2.20
Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology (1997) 2.07
Significance of resection margin in hepatectomy for hepatocellular carcinoma: A critical reappraisal. Ann Surg (2000) 2.01
Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology (2011) 1.94
Proteomic analysis of serum associated fucosylated glycoproteins in the development of primary hepatocellular carcinoma. J Proteome Res (2006) 1.93
Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. Cancer (1994) 1.81
Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev (2009) 1.79
Identification of novel serum biomarkers of hepatocellular carcinoma using glycomic analysis. Hepatology (2013) 1.76
Serum markers of hepatocellular carcinoma. Dig Dis Sci (2010) 1.76
Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature. J Cancer Res Clin Oncol (2004) 1.75
Lectin-based structural glycomics: glycoproteomics and glycan profiling. Glycoconj J (2004) 1.71
Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut (2010) 1.67
Disease- and cell-specific expression of GP73 in human liver disease. Am J Gastroenterol (2004) 1.65
Core fucosylation regulates epidermal growth factor receptor-mediated intracellular signaling. J Biol Chem (2005) 1.61
Trends in primary liver cancer. Lancet (1998) 1.56
Lectin capture strategies combined with mass spectrometry for the discovery of serum glycoprotein biomarkers. Mol Cell Proteomics (2006) 1.56
SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology (2005) 1.55
Detection of hepatocellular carcinoma using glycomic analysis. Clin Cancer Res (2009) 1.52
Osteopontin overexpression in breast cancer: knowledge gained and possible implications for clinical management. J Cell Biochem (2007) 1.48
AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol (2010) 1.44
Suppression of lung metastasis of B16 mouse melanoma by N-acetylglucosaminyltransferase III gene transfection. Proc Natl Acad Sci U S A (1995) 1.44
Changing incidence of hepatocellular carcinoma in Japan. Cancer Res (1987) 1.44
Relationship between elevated FX expression and increased production of GDP-L-fucose, a common donor substrate for fucosylation in human hepatocellular carcinoma and hepatoma cell lines. Cancer Res (2003) 1.38
N-glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus. Hepatology (2007) 1.37
Linkage specific fucosylation of alpha-1-antitrypsin in liver cirrhosis and cancer patients: implications for a biomarker of hepatocellular carcinoma. PLoS One (2010) 1.34
Heat-shock protein 27: a potential biomarker for hepatocellular carcinoma identified by serum proteome analysis. Proteomics (2005) 1.33
Elevated plasma osteopontin levels in patients with hepatocellular carcinoma. Am J Gastroenterol (2006) 1.28
Highly enhanced fucosylation of serum glycoproteins in patients with hepatocellular carcinoma. J Gastroenterol Hepatol (1999) 1.28
Golgi protein 73 versus alpha-fetoprotein as a biomarker for hepatocellular carcinoma: a diagnostic meta-analysis. BMC Cancer (2012) 1.27
Fucosylation of N-glycans regulates the secretion of hepatic glycoproteins into bile ducts. J Biol Chem (2006) 1.26
GP73, a resident Golgi glycoprotein, is sensibility and specificity for hepatocellular carcinoma of diagnosis in a hepatitis B-endemic Asian population. Med Oncol (2009) 1.26
The alpha1-6-fucosyltransferase gene and its biological significance. Biochim Biophys Acta (1999) 1.24
Correlation of hepatitis virus serologic status with clinicopathologic features in patients undergoing hepatectomy for hepatocellular carcinoma. Cancer (1997) 1.23
A distinct repertoire of autoantibodies in hepatocellular carcinoma identified by proteomic analysis. Mol Cell Proteomics (2002) 1.22
Fucosyltransferase 8 as a functional regulator of nonsmall cell lung cancer. Proc Natl Acad Sci U S A (2012) 1.22
Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia. Glycobiology (2010) 1.20
Proteome analysis of hepatocellular carcinoma cell strains, MHCC97-H and MHCC97-L, with different metastasis potentials. Proteomics (2004) 1.19
Peroxiredoxins, a novel protein family in lung cancer. Int J Cancer (2004) 1.19
Hepatocellular carcinoma. Hepatology (1998) 1.16
Peroxiredoxin 1 interacts with androgen receptor and enhances its transactivation. Cancer Res (2007) 1.15
Serological AFP/Golgi protein 73 could be a new diagnostic parameter of hepatic diseases. Int J Cancer (2011) 1.15
The fucosylation index of alpha-fetoprotein as a possible prognostic indicator for patients with hepatocellular carcinoma. Cancer (1998) 1.14
Glycomic characterization of prostate-specific antigen and prostatic acid phosphatase in prostate cancer and benign disease seminal plasma fluids. J Proteome Res (2009) 1.13
Mass spectrometric approach for screening modifications of total serum N-glycome in human diseases: application to cirrhosis. Glycobiology (2005) 1.13
Increased Golgi protein 73 expression in hepatocellular carcinoma tissue correlates with tumor aggression but not survival. J Gastroenterol Hepatol (2011) 1.13
Quantitative liquid chromatography-mass spectrometry-multiple reaction monitoring (LC-MS-MRM) analysis of site-specific glycoforms of haptoglobin in liver disease. Mol Cell Proteomics (2013) 1.11
Diagnostic value of the hemopexin N-glycan profile in hepatocellular carcinoma patients. Clin Chem (2010) 1.09
Detection and identification of tumor-associated protein variants in human hepatocellular carcinomas. Hepatology (2004) 1.09
Site-specific glycoforms of haptoglobin in liver cirrhosis and hepatocellular carcinoma. Mol Cell Proteomics (2013) 1.09
Proteomic alterations of the variants of human aldehyde dehydrogenase isozymes correlate with hepatocellular carcinoma. Int J Cancer (2002) 1.09
Proteomic profiling of heat shock protein 70 family members as biomarkers for hepatitis C virus-related hepatocellular carcinoma. Proteomics (2003) 1.07
Identification and confirmation of biomarkers using an integrated platform for quantitative analysis of glycoproteins and their glycosylations. J Proteome Res (2010) 1.05
Analysis of serum haptoglobin fucosylation in hepatocellular carcinoma and liver cirrhosis of different etiologies. J Proteome Res (2014) 1.05
Management of hepatitis C: current and future perspectives. J Hepatol (1999) 1.04
Proteomic signature corresponding to alpha fetoprotein expression in liver cancer cells. Hepatology (2004) 1.04
Sugar chains of human cord serum alpha-fetoprotein: characteristics of N-linked sugar chains of glycoproteins produced in human liver and hepatocellular carcinomas. Cancer Res (1993) 1.04
Quantitative analysis of elevated serum Golgi protein-73 expression in patients with liver diseases. Ann Clin Biochem (2008) 1.03
A comparative evaluation of Golgi protein-73, fucosylated hemopexin, α-fetoprotein, and PIVKA-II in the serum of patients with chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Clin Chem Lab Med (2011) 1.03
Increased levels of tetra-antennary N-linked glycan but not core fucosylation are associated with hepatocellular carcinoma tissue. Cancer Epidemiol Biomarkers Prev (2012) 1.02
Proteome analysis of hepatocellular carcinoma by laser capture microdissection. Proteomics (2006) 1.02
Proteomic analysis and molecular characterization of tissue ferritin light chain in hepatocellular carcinoma. Hepatology (2002) 1.01
The fucosylation index of alpha-fetoprotein and its usefulness in the early diagnosis of hepatocellular carcinoma. Cancer (1988) 0.99
A proteomic approach for the discovery of early detection markers of hepatocellular carcinoma. Dis Markers (2001) 0.99
Exploring site-specific N-glycosylation microheterogeneity of haptoglobin using glycopeptide CID tandem mass spectra and glycan database search. J Proteome Res (2013) 0.99
Peroxiredoxins in the lung with emphasis on peroxiredoxin VI. Subcell Biochem (2007) 0.98
Expression of alpha1,6-fucosyltransferase (FUT8) in papillary carcinoma of the thyroid: its linkage to biological aggressiveness and anaplastic transformation. Cancer Lett (2003) 0.98
5-AZA-2'-deoxycytidine induced demethylation influences N-glycosylation of secreted glycoproteins in ovarian cancer. Epigenetics (2011) 0.98
Fucosylated haptoglobin is a novel type of cancer biomarker linked to the prognosis after an operation in colorectal cancer. Cancer (2011) 0.98
Clinical application of a lectin-antibody ELISA to measure fucosylated haptoglobin in sera of patients with pancreatic cancer. Clin Chem Lab Med (2010) 0.98
Diagnostic significance of plasma osteopontin in hepatitis C virus-related hepatocellular carcinoma. Ann Hepatol (2011) 0.97
Complex N-glycan and metabolic control in tumor cells. Cancer Res (2007) 0.97
Haptoglobin. A potential reporter molecule for glycosylation changes in disease. Adv Exp Med Biol (1995) 0.97
The fucosylation index of serum alpha-fetoprotein as useful prognostic factor in patients with hepatocellular carcinoma in special reference to chronological changes. Hepatol Res (2002) 0.96
Retracted Diagnostic and prognostic validity of Golgi protein 73 in hepatocellular carcinoma. Digestion (2010) 0.96
A study of diagnostic value of golgi protein GP73 and its genetic assay in primary hepatic carcinoma. Technol Cancer Res Treat (2011) 0.96
Integrated glycoproteomics demonstrates fucosylated serum paraoxonase 1 alterations in small cell lung cancer. Mol Cell Proteomics (2013) 0.96
Peroxiredoxin 2: a potential biomarker for early diagnosis of hepatitis B virus related liver fibrosis identified by proteomic analysis of the plasma. BMC Gastroenterol (2010) 0.95
A lectin-coupled, targeted proteomic mass spectrometry (MRM MS) platform for identification of multiple liver cancer biomarkers in human plasma. J Proteomics (2012) 0.95